▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #301 by analyst upside · 2026-09-26
KPRX
Kiora Pharmaceuticals, Inc.
Healthcare · Market Cap $12M · P/E 0x
ANALYST PRICE TARGET
+356.3%
implied upside to consensus target
Current Price $2.63
Consensus Target $12.0
Bull Target $12.0
Bear Target $12.0
Analysts Covering 1
ANALYST CONSENSUS - STRONG BUY
Strong Buy
1
Buy
0
Hold
0
Sell
0
52-Week Low $1.76
52-Week High $2.95
YTD Return +30.2%
FUNDAMENTALS
Market Cap $12M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.45
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.76
52-Week High $2.95
Current Price $2.63
Bear Target $12.0
Bull Target $12.0
● Now $2.63 ● Target $12.0
TRADING DATA
Avg Volume 18K
YTD Return +30.2%
Analyst Count 1
Consensus Strong Buy
Upside to Target +356.3%
Last Updated 2026-09-26

ANALYST SUMMARY

Kiora Pharmaceuticals, Inc. (KPRX) is currently trading at $2.63 with a Wall Street consensus price target of $12.0, implying potential upside of 356.3% over the next 12 months. 1 analysts currently cover KPRX, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $12.0.

KPRX operates in the Healthcare sector with a market capitalisation of $12M. The stock is up 30.2% year-to-date and is currently trading near the upper end of its 52-week range of $1.76 – $2.95.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for KPRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2025-09-02 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-28 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-11-12 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-08-22 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2024-07-23 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →